‘Breathe is honored to have been selected as a Winner of a 2012 Medical Design Excellence Awards. To be acknowledged by MDEA underscores the innovative and unique areas of the Breathe NIOV System. We believe our technology has the potential to allow individuals with respiratory insufficiency to experience greater flexibility and participation in activities of everyday living,’ stated Larry Mastrovich, Breathe Technologies, CEO and President. Multiple clinical research have demonstrated that sufferers with respiratory insufficiency can reap the benefits of noninvasive ventilation. Existing ventilator technology is overweight and bulky to assist in patient ambulation practically.To identify individuals with the T790M mutation. Related StoriesMeat-rich diet plan may increase kidney tumor riskOvarian cancer patients with a history of oral contraceptive make use of have got better outcomesCornell biomedical engineers develop 'very natural killer cells' to destroy cancers cells in lymph nodes While the development of EGFR tyrosine kinase inhibitor therapy for NSCLC patients with EGFR mutations is a major advance, resistance develops after about a full calendar year and is a major obstacle lung oncologists encounter in the clinic each complete day, said Lecia Sequist, Thoracic Medical Oncologist at Massachusetts General Cancers Center, Assistant Professor of Medicine at Harvard Medical School and an investigator in the scholarly study.